167 related articles for article (PubMed ID: 25447626)
21. Comparison between valsartan and amlodipine regarding cardiovascular morbidity and mortality in hypertensive patients with glucose intolerance: NAGOYA HEART Study.
Muramatsu T; Matsushita K; Yamashita K; Kondo T; Maeda K; Shintani S; Ichimiya S; Ohno M; Sone T; Ikeda N; Watarai M; Murohara T;
Hypertension; 2012 Mar; 59(3):580-6. PubMed ID: 22232134
[TBL] [Abstract][Full Text] [Related]
22. Effect of valsartan on kidney outcomes in people with impaired glucose tolerance.
Currie G; Bethel MA; Holzhauer B; Haffner SM; Holman RR; McMurray JJV
Diabetes Obes Metab; 2017 Jun; 19(6):791-799. PubMed ID: 28093841
[TBL] [Abstract][Full Text] [Related]
23. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
Aguilar D; Solomon SD; Køber L; Rouleau JL; Skali H; McMurray JJ; Francis GS; Henis M; O'Connor CM; Diaz R; Belenkov YN; Varshavsky S; Leimberger JD; Velazquez EJ; Califf RM; Pfeffer MA
Circulation; 2004 Sep; 110(12):1572-8. PubMed ID: 15364810
[TBL] [Abstract][Full Text] [Related]
24. Noncardiovascular deaths are more common than cardiovascular deaths in patients with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: Insights from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial.
Sharma A; de Souza Brito F; Sun JL; Thomas L; Haffner S; Holman RR; Lopes RD
Am Heart J; 2017 Apr; 186():73-82. PubMed ID: 28454835
[TBL] [Abstract][Full Text] [Related]
25. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M
J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836
[TBL] [Abstract][Full Text] [Related]
26. Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience.
Stephenson K; Skali H; McMurray JJ; Velazquez EJ; Aylward PG; Kober L; Van de Werf F; White HD; Pieper KS; Califf RM; Solomon SD; Pfeffer MA
Heart Rhythm; 2007 Mar; 4(3):308-13. PubMed ID: 17341394
[TBL] [Abstract][Full Text] [Related]
27. Enhanced cardiovascular protective effects of valsartan in high-risk hypertensive patients with left ventricular hypertrophy--sub-analysis of the KYOTO HEART study.
Shiraishi J; Sawada T; Kimura S; Yamada H; Matsubara H;
Circ J; 2011; 75(4):806-14. PubMed ID: 21436597
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, randomized, double-blind, noninferiority study.
Lee IT; Hung YJ; Chen JF; Wang CY; Lee WJ; Sheu WH
Clin Ther; 2012 Aug; 34(8):1735-50. PubMed ID: 22784975
[TBL] [Abstract][Full Text] [Related]
29. Physical activity as a determinant of fasting and 2-h post-challenge glucose: a prospective cohort analysis of the NAVIGATOR trial.
Yates T; Davies MJ; Haffner SM; Schulte PJ; Thomas L; Huffman KM; Bales CW; Preiss D; Califf RM; Holman RR; McMurray JJ; Bethel MA; Tuomilehto J; Kraus WE
Diabet Med; 2015 Aug; 32(8):1090-6. PubMed ID: 25818859
[TBL] [Abstract][Full Text] [Related]
30. Incidence of major adverse cardiovascular events among patients with provoked and unprovoked venous thromboembolism: Findings from the Registro Informatizado de Enfermedad Tromboembólica Registry.
Golemi I; Cote L; Iftikhar O; Brenner B; Tafur A; Bikdeli B; Fernández-Capitán C; Pedrajas JM; Otero R; Quintavalla R; Monreal M;
J Vasc Surg Venous Lymphat Disord; 2020 May; 8(3):353-359.e1. PubMed ID: 31784355
[TBL] [Abstract][Full Text] [Related]
31. Prospective relationships between body weight and physical activity: an observational analysis from the NAVIGATOR study.
Preiss D; Thomas LE; Wojdyla DM; Haffner SM; Gill JM; Yates T; Davies MJ; Holman RR; McMurray JJ; Califf RM; Kraus WE;
BMJ Open; 2015 Aug; 5(8):e007901. PubMed ID: 26275900
[TBL] [Abstract][Full Text] [Related]
32. Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction).
Lewis EF; Li Y; Pfeffer MA; Solomon SD; Weinfurt KP; Velazquez EJ; Califf RM; Rouleau JL; Kober L; White HD; Schulman KA; Reed SD
JACC Heart Fail; 2014 Apr; 2(2):159-65. PubMed ID: 24720924
[TBL] [Abstract][Full Text] [Related]
33. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design.
Mann J; Julius S
Blood Press; 1998 May; 7(3):176-83. PubMed ID: 9758088
[TBL] [Abstract][Full Text] [Related]
34. [Effects of nateglinide in impaired glucose tolerance subjects].
Hirose T
Nihon Rinsho; 2005 Feb; 63 Suppl 2():438-43. PubMed ID: 15779419
[No Abstract] [Full Text] [Related]
35. Nateglinide combination therapy with basal insulin and metformin in patients with Type 2 diabetes.
Juurinen L; Tiikkainen M; Saltevo J; Nikkilä K; Lanki H; Leppävuori E; Kock T; Teikari-Myyrä T; Kauppinen-Mäkelin R; Kotronen A; Yki-Järvinen H
Diabet Med; 2009 Apr; 26(4):409-15. PubMed ID: 19388972
[TBL] [Abstract][Full Text] [Related]
36. The Valsartan Antihypertensive Long-Term Use Evaluation trial: a study in contrasts.
Sica DA
Hypertension; 2006 Sep; 48(3):362-3. PubMed ID: 16864742
[No Abstract] [Full Text] [Related]
37. Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial.
Preiss D; Thomas LE; Sun JL; Haffner SM; Holman RR; Standl E; Leiter LA; Mazzone T; Rutten GE; Tognoni G; Martinez FA; Chiang FT; Califf RM; McMurray JJ
BMJ Open; 2012; 2(6):. PubMed ID: 23204139
[TBL] [Abstract][Full Text] [Related]
38. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction.
Anavekar NS; McMurray JJ; Velazquez EJ; Solomon SD; Kober L; Rouleau JL; White HD; Nordlander R; Maggioni A; Dickstein K; Zelenkofske S; Leimberger JD; Califf RM; Pfeffer MA
N Engl J Med; 2004 Sep; 351(13):1285-95. PubMed ID: 15385655
[TBL] [Abstract][Full Text] [Related]
39. Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin.
Hirschberg Y; Karara AH; Pietri AO; McLeod JF
Diabetes Care; 2000 Mar; 23(3):349-53. PubMed ID: 10868864
[TBL] [Abstract][Full Text] [Related]
40. Valsartan improves {beta}-cell function and insulin sensitivity in subjects with impaired glucose metabolism: a randomized controlled trial.
van der Zijl NJ; Moors CC; Goossens GH; Hermans MM; Blaak EE; Diamant M
Diabetes Care; 2011 Apr; 34(4):845-51. PubMed ID: 21330640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
